Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 18/20 | 0.78 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.44 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.38 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.38 |
| ▸ | ITGAL | P20701 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7893662 | 1.00 | SLC6A9 (0.78) | SLC6A9SLC6A5ITGB2ICAM1ITGAL | |
| SCHEMBL2605221 | 0.90 | SLC6A9 (0.80) | SLC6A9SLC6A5ITGB2ICAM1ITGAL | |
| SCHEMBL2605198 | 0.88 | SLC6A9 (1.00) | SLC6A9SLC6A5ITGB2ICAM1ITGAL | |
| SCHEMBL2605352 | 0.88 | SLC6A9 (1.00) | SLC6A9SLC6A5ITGB2ICAM1ITGAL | |
| SCHEMBL2605274 | 0.88 | SLC6A9 (0.64) | SLC6A9SLC6A5 | |
| SCHEMBL2605303 | 0.86 | SLC6A9 (1.00) | SLC6A9SLC6A5L3MBTL1 | |
| SCHEMBL2605184 | 0.86 | SLC6A9 (1.00) | SLC6A9SLC6A5L3MBTL1 | |
| SCHEMBL2605297 | 0.86 | SLC6A9 (0.74) | SLC6A9SLC6A5 | |
| SCHEMBL2605263 | 0.84 | SLC6A9 (0.72) | SLC6A9SLC6A5 | |
| SCHEMBL2605283 | 0.84 | SLC6A9 (0.70) | SLC6A9SLC6A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120094995-A1 | 2-AZA-BICYCLO[2.2.1]HEPTANE COMPOUNDS AND USES THEREOF | ASTRAZENECA AB (SE) | 2012-04-19 | — | — | US | disclosed |
| US-20120094995-A1 | 2-AZA-BICYCLO[2.2.1]HEPTANE COMPOUNDS AND USES THEREOF | ASTRAZENECA AB (SE) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094995-A1 | 2-AZA-BICYCLO[2.2.1]HEPTANE COMPOUNDS AND USES THEREOF | SLC1A2, B4GALT1, SLC6A1 | SLC6A9 50/4885SLC6A5 33/4885ITGB2 1816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.